Neoadjuvant chemotherapy rather than neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer with high tumor burden.
We investigated the characteristics of locally advanced rectal cancer (LARC) patients who had received neoadjuvant chemoradiotherapy (NCRT), and who developed early metastasis during the perioperative period. LARC who were treated and followed-up were included in this study. Patients' files were reviewed retrospectively and the data on patients were recorded. Totally, 182 stage II and III rectal cancer patients who received NCRT were retrospectively evaluated. Seventeen (9.3%) patients were metastatic during the perioperative period. Of them, metastases developed preoperatively in 3 (17.6%) patients after NCRT, while 14 (82.4%) developed metastases postoperatively before adjuvant chemotherapy (CT). Twelve (70.6%) patients had clinical stage T4N+ disease. The median time interval between pathological diagnosis and metastasis development was 4 (3-5) months. The median survival was 24 months. More effective treatment is warranted in patients with LARC with a high tumor burden.